Honing in on the Appeal Process to Improve Access to Anti-VEGF Therapy for Patients with AMD

Honing in on the Appeal Process to Improve Access to Anti-VEGF Therapy for Patients with AMD is organized by CME Outfitters, LLC.

Premiere Date: Thursday, November 21, 2019
Credit Expiration Date: Saturday, December 31, 2020

This activity offers CE credit for:
• Physicians (CME)
• Pharmacists (ACPE)
• ABO (MOC)
• Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™.

Credit Information:
CME Credit (Physicians):
CME Outfitters, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0.5 contact hours (0.05 CEUs) Universal Activity Number:
Enduring: 0376-0000-19-067-H01-P

Statement of Need:
Step therapy requirements have limited patient access to FDA-approved, anti–vascular endothelial growth factor (VEGF) agents for the treatment of AMD. Prior authorization requests for these therapies are commonly denied. Hence, it is important that clinicians be aware of the approaches to overcome these barriers and implement systematic and clinically supported appeals that ensure uninterrupted anti-VEGF therapy for patients with AMD. 

In the third module of this CME Outfitters Snack series, expert faculty focus on developing and implementing strategies for appeals in order to reduce treatment delays.

Learning Objectives:
At the end of this CE activity, participants should be able to:
• Develop and implement approaches for a systematic and clinically supported appeal to ensure uninterrupted anti-VEGF therapy for patients with AMD.
The following learning objective pertains only to those requesting CPE credit:
• Describe approaches for a systematic and clinically supported appeal to ensure uninterrupted anti-VEGF therapy for patients with AMD.